Advertisement
Canada markets open in 6 hours 21 minutes

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7328
    +0.0005 (+0.07%)
     

  • CRUDE OIL

    83.96
    +0.39 (+0.47%)
     

  • Bitcoin CAD

    87,800.45
    +101.12 (+0.12%)
     

  • CMC Crypto 200

    1,390.71
    -5.82 (-0.42%)
     

  • GOLD FUTURES

    2,352.80
    +10.30 (+0.44%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ futures

    17,775.25
    +207.75 (+1.18%)
     

  • VOLATILITY

    15.37
    0.00 (0.00%)
     

  • FTSE

    8,078.86
    0.00 (0.00%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6825
    +0.0004 (+0.06%)
     

TÜV Rheinland: Notified Body for In-Vitro Diagnostics

TUV Rheinland
·2 min read

TÜV Rheinland LGA Products GmbH is Notified Body for the EU Regulation on In Vitro Diagnostics (IVDR) 2017/746 / Information at http://www.tuv.com/en/IVDR

COLOGNE, Germany and LITTLETON, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- TÜV Rheinland LGA Products GmbH is Notified Body for the EU Regulation on In Vitro Diagnostics (IVDR) 2017/746.

“We are currently one of the few Notified Bodies worldwide for the new IVDR,” says Dr. Wilma Hartung, Managing Director Medical Devices at TÜV Rheinland.

The IVDR regulation will replace the currently valid IVD Directive (98/79/EC) from 26 May 2022. The new regulation redefines the system for classifying products fundamentally. Manufacturers must now involve a Notified Body in the conformity assessment for a much larger number of in-vitro diagnostics. Information on the notification is available on the NANDO website of the European Union. NANDO stands for “New Approach Notified and Designated Organisations.”

ADVERTISEMENT

A lot to be done until the IVDR becomes effective
“By the time enforcement of the new regulation will begin in May 2022, the Notified Bodies will have to test a large number of in-vitro diagnostics manufacturers that are to be certified for the first time and with them a flood of technical documentation,” explains Dr. Hartung. “Even if the year 2022 still seems a long way off, we have already learned with the European Medical Device Directive MDR that manufacturers must adapt to the new requirements at a very early stage. This includes the early involvement of a Notified Body for the IVDR.”

With almost 40 years of experience in in-vitro diagnostic device assessments, TÜV Rheinland is one of the most trusted independent testing service providers for major global brands. More information is available at http://www.tuv.com/en/IVDR at TÜV Rheinland.

About TUV:
TÜV Rheinland stands for safety and quality in virtually all areas of business and life. Founded almost 150 years ago, the company is one of the world’s leading testing service providers with more than 20,000 employees and annual revenues of 2 billion euros. TÜV Rheinland’s highly qualified experts test technical systems and products around the world, support innovations in technology and business, train people in numerous professions and certify management systems according to international standards. In doing so, the independent experts generate trust in products as well as processes across global value-adding chains and the flow of commodities. Since 2006, TÜV Rheinland has been a member of the United Nations Global Compact to promote sustainability and combat corruption. Website: www.tuv.com

Contact for editorial questions:
Ralf Diekmann, TÜV Rheinland, Press
Tel.: +49 (0)221/806-1972

Current press releases as well as photo and video footage are available on request by email to presse@de.tuv.com or on www.tuv.com/press.